Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in
participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made
chemical that is like oxytocin). This study will also evaluate the safety and tolerability of
LV-101.